|
Jul 24
|
Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
|
|
Jul 22
|
Outlook Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
|
|
Jul 22
|
JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live
|
|
Jul 18
|
Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) biggest owners are retail investors who got richer after stock soared 14% last week
|
|
Jul 1
|
Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer
|
|
Jun 18
|
Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event
|
|
May 23
|
Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering
|
|
May 22
|
Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants
|
|
Apr 8
|
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
|
|
Feb 19
|
Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
|
|
Jan 16
|
Sector Update: Health Care Stocks Rise Late Afternoon
|
|
Jan 16
|
Outlook Therapeutics Shares Fall After Reporting Trial Results for ONS-5010 in Wet AMD
|
|
Jan 16
|
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
|
|
Jan 16
|
Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial
|
|
Dec 30
|
Outlook Therapeutics Stock Surges on Positive Outlook Despite Loss
|
|
Sep 13
|
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series
|
|
Jul 30
|
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024
|
|
Jun 19
|
Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) largest shareholders are individual investors with 31% ownership, private equity firms own 31%
|
|
May 15
|
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update
|
|
May 13
|
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD
|